Grade 3 or higher rash and diarrhea occurred in 0.3% of patients who received placebo and fulvestrant.
Adverse events sometimes led to treatment discontinuation.
This occurred in 13.0% of the capivasertib-fulvestrant group and 2.3% of the placebo-fulvestrant group.
In the overall population, the median PFS was 7.2 months in the capivasertib-fulvestrant group versus 3.6 months in the placebo-fulvestrant group (HR, 0.60; 95% CI, 0.51–0.71;P< .001).[32][Level of evidence B1] In thePIK3CA/AKT/PTENpathway-altered population, the median PFS was 7.3 months in the capivasertib-fulvestrant group and 3.1 months in the placebo-fulvestrant group (HR, 0.50; 95% CI, 0.38–0.65;P< .001).